HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $12.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on IN8bio (NASDAQ:INAB) and maintained a price target of $12.5.
June 04, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on IN8bio and maintained a price target of $12.5, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $12.5 price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors, suggesting confidence in IN8bio's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100